Hung Trinh Shares a 2025 Update on RNA-Based Cancer Vaccines
Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update
RNA-based cancer vaccines are a breakthrough cancer treatment that trains the immune system to recognize and attack specific cancer cells. Recent clinical trials show impressive results, with one melanoma treatment reducing cancer recurrence by 44% when combined with existing immunotherapy. The field gained significant momentum in 2024–2025 with major advances in pancreatic and brain cancer treatments, supported by over 120 ongoing clinical trials.
These vaccines utilize different types of RNA to create personalized treatments tailored to each patient’s unique tumor, although they remain expensive, costing over $100,000 per patient. Artificial intelligence is helping scientists identify the best cancer targets while manufacturing improvements have reduced production time from nine weeks to under four weeks.
With over 60 treatments in development and first commercial approvals expected by 2029, RNA cancer vaccines represent a significant advancement in personalized cancer care, offering new hope for patients with various types of cancer.”
Title: Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update
Aurhors: Matthias Magoola, Sarfaraz K. Niazi
Read the Full Article on MDPI.
More posts featuring Hung Trinh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023